Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribiero MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. Ghione P, et al. Among authors: palomba ml. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):e191-e195.e6. doi: 10.1016/j.clml.2024.01.011. Epub 2024 Jan 24. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38365528
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, Beaupre DM, Neuenburg JK, Palomba ML. Fowler NH, et al. Among authors: palomba ml. Br J Haematol. 2020 May;189(4):650-660. doi: 10.1111/bjh.16424. Epub 2020 Mar 16. Br J Haematol. 2020. PMID: 32180219 Free PMC article.
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
Sermer D, Bobillo S, Dogan A, Zhang Y, Seshan V, Lavery JA, Batlevi C, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Palomba ML, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A. Sermer D, et al. Among authors: palomba ml. Blood Adv. 2020 Jul 28;4(14):3382-3390. doi: 10.1182/bloodadvances.2020001551. Blood Adv. 2020. PMID: 32722781 Free PMC article.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Bobillo S, Joffe E, Lavery JA, Sermer D, Ghione P, Noy A, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Moskowitz A, Owens CN, Palomba ML, Batlevi CL, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Seshan VE, Younes A. Bobillo S, et al. Among authors: palomba ml. Blood. 2021 Jan 7;137(1):39-48. doi: 10.1182/blood.2020005112. Blood. 2021. PMID: 32730585 Free PMC article.
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
Palomba ML, Jun MP, Lymp J, Nguyen A, McGarvey N, Gitlin M, Pelletier C, Keating SJ, Godwin J. Palomba ML, et al. Leuk Lymphoma. 2021 Sep;62(9):2169-2176. doi: 10.1080/10428194.2021.1910686. Epub 2021 May 21. Leuk Lymphoma. 2021. PMID: 34018458 Free PMC article.
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Bobillo S, et al. Among authors: palomba ml. Blood Cancer J. 2021 Jun 16;11(6):113. doi: 10.1038/s41408-021-00506-3. Blood Cancer J. 2021. PMID: 34135307 Free PMC article.
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
Palomba ML, Till BG, Park SI, Morschhauser F, Cartron G, Marks R, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Popplewell LL. Palomba ML, et al. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e443-e451. doi: 10.1016/j.clml.2021.12.010. Epub 2021 Dec 24. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35031227 Free article. Clinical Trial.
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ, Jung AS, Kanters S, Snider JT, Neelapu SS, Ribeiro MT, Brookhart MA, Ghesquieres H, Radford J, Gribben JG. Ghione P, et al. Among authors: palomba ml. Blood. 2022 Aug 25;140(8):851-860. doi: 10.1182/blood.2021014375. Blood. 2022. PMID: 35679476 Free PMC article.
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, Kanters S, Deighton K, Hatswell A, Ma L, Limbrick-Oldfield EH, Snider JT, Wade SW, Riberio MT, Radford J, Beygi S, Gribben J. Ghione P, et al. Among authors: palomba ml. Haematologica. 2023 Mar 1;108(3):822-832. doi: 10.3324/haematol.2022.281421. Haematologica. 2023. PMID: 36263843 Free PMC article.
116 results